July 8, 2022
Mochida Senior Executive Managing Officer Keiichi Sagisaka Mochida Pharmaceutical’s top two products - Lexapro (escitalopram) and Lialda (mesalazine) - are expected to go off-patent in the next few years. The drug maker says it weighs authorized generic (AG) options for...read more